Moreover, wound healing and matrigel transmigration assays showed that migration rate of CD133-cancer cells with pCMV-snoRA42 was higher compared with CD133-cancer cells with pCMV control (Figure 5 D).
The gain-of-function experiments indicate that upregulation of snoRA42 would enhance the in vivo tumorigenicity of CD133- cancer cells isolated from NSCLC cells.